Ramchand SK, et al. - Researchers conducted this single-site, open-label, randomized controlled trial to compare the individual rates of areal bone mineral density (aBMD) response between the treatment groups [standard-dose (SD) and high-dose (HD)]. For this investigation, postmenopausal women received either teriparatide 20-μg daily (SD) or 40-μg daily (HD) given months 0 through 9, overlapped with denosumab 60 mg, given months 3 through 15. Sixty postmenopausal women with osteoporosis completing all study visits. More women treated with the HD regimen achieved clinically meaningful and rapid gains in hip and spine aBMD relative to the SD regimen. Such results suggest that this approach will bring unique benefits in postmenopausal osteoporosis treatment.